Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Sankt Augustin – page 55

1 118 clinical trials in Sankt Augustin, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Sankt Augustin at a glance
1 118
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 118 trials in Sankt Augustin

Open in trial search

Small cell lung cancer extensive stage

Not recruiting

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Novartis Pharma AG

Systemic sclerosis pulmonary

Not recruiting

Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Diabetic retinal oedema

Not recruiting

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Small cell lung cancer

Not recruiting

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Therapeutics Inc.

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Muscle strain+3

Not recruiting

Study of Esflurbiprofen Hydrogel Patch Adhesion in Healthy Volunteers

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Esflurbiprofen
  • Sponsor:Teikoku Seiyaku Co. Ltd.

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Sankt Augustin

What the registry says about research in the country

01 Pediatric Rheumatology

Clinical trials focusing on innovative treatments for juvenile arthritis conditions, including studies of medications like baricitinib, ustekinumab, and bimekizumab for various forms of JIA.

  • Juvenile Psoriatic Arthritis
  • Systemic Juvenile Idiopathic Arthritis
  • Enthesitis-related Arthritis

Research aims to evaluate drug efficacy and safety in pediatric populations with autoimmune conditions.

02 Pediatric Oncology

Comprehensive studies on childhood cancers, with particular focus on leukemia and lymphoma treatments, including novel therapeutic approaches and combination therapies.

  • Acute Lymphoblastic Leukemia
  • B-cell Lymphoma
  • Myeloid Leukemia

Investigations include targeted therapies and personalized treatment protocols for various cancer stages.

03 Neuro-Oncology

Specialized research into brain and nervous system tumors, focusing on ependymoma and medulloblastoma treatment strategies.

  • Medulloblastoma
  • Intracranial Ependymoma
  • Neuroblastoma

Studies evaluate surgical outcomes, radiation therapy approaches, and chemotherapy effectiveness.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.